Literature DB >> 7751718

Toxicity of Streptococcus pneumoniae in neurons, astrocytes, and microglia in vitro.

Y S Kim1, S Kennedy, M G Täuber.   

Abstract

The toxicity of pneumococci and endotoxin in primary cultures of rat neurons, astrocytes, and microglia and in a human astrocyte and two human glial cell lines was determined. Heat-inactivated, rough pneumococci (up to 10(8) cfu/mL) or their cell wall (up to 50 micrograms/mL) produced dose-dependent toxicity after 48 h in microglial cells and to a lesser extent in astrocytes but not in neurons. Toxicity was similar for equivalent doses of heat-inactivated organisms and pneumococcal cell wall, but time-course experiments showed significant differences between the two stimuli. Endotoxin at concentrations of up to 5 micrograms/mL did not induce significant toxicity in any of the cells. Thus, pneumococci can induce toxicity in two brain cell types, microglia and astrocytes, and the pneumococcal cell wall appears to mediate toxicity. Direct toxic effects of bacteria on brain cells may in part be responsible for brain injury during meningitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751718     DOI: 10.1093/infdis/171.5.1363

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Cell wall-mediated neuronal damage in early sepsis.

Authors:  Carlos J Orihuela; Sophie Fillon; S Hope Smith-Sielicki; Karim C El Kasmi; Geli Gao; Konstantinos Soulis; Avinash Patil; Peter J Murray; Elaine I Tuomanen
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response.

Authors:  Jagath L Kadurugamuwa; Kshitij Modi; Olivier Coquoz; Brad Rice; Steven Smith; Pamela R Contag; Tony Purchio
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Gemifloxacin is effective in experimental pneumococcal meningitis.

Authors:  A Smirnov; A Wellmer; J Gerber; K Maier; S Henne; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 4.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 5.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production.

Authors:  Y S Kim; M G Täuber
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

7.  Pathogenesis of gram-positive bacterial endophthalmitis.

Authors:  M C Callegan; M C Booth; B D Jett; M S Gilmore
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.

Authors:  K Stuertz; H Schmidt; H Eiffert; P Schwartz; M Mäder; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 9.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

10.  Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone.

Authors:  Joachim Gerber; Karin Pohl; Valeska Sander; Stephanie Bunkowski; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.